Nootropil, 800 mg 30 pcs

Stroke sequelae, Hangover, Alcoholism, Nausea, Dizziness, Headache, Impaired cerebral circulation, Tinnitus, Concussion and other brain injuries, Attention and memory disorders, Alzheimer’s disease, Learning disabilities, Acquired dementia, Disorientation in space For adults:

– Symptomatic treatment of psychorganic syndrome, symptoms of which include decreased memory, decreased concentration and decreased general activity

– Treatment of cortical myoclonias, as mono- or complex therapy

– Treatment of vertigo and related balance disorders, except vertigo of vascular and mental origin

– Prevention and treatment of sickle cell vasculo-occlusive crises

For children:

– prevention and treatment of sickle cell vascular occlusive crises

– treatment of dyslexia (in complex therapy) – from 8 years of age

Indications

For adults:

– symptomatic treatment of psychoorganic syndrome, the symptoms of which include decreased memory, decreased concentration and decreased overall activity

– treatment of cortical myoclonus, as mono- or complex therapy

– treatment of dizziness and related balance disorders, with the exception of dizziness of vascular and mental origin

– prevention and treatment of sickle cell vascular-occlusive crises

For children:

– prevention and treatment of sickle cell vascular-occlusive crises

– treatment of dyslexia (in complex therapy) – from 8 years of age

Pharmacological effect

Pharmacotherapeutic group: Psychostimulants and other nootropics. Piracetam.

Special instructions

Caution should be exercised when prescribing the drug to patients with impaired hemostasis, during major surgery, or to patients with symptoms of severe bleeding.

When treating patients with cortical myoclonus, abrupt discontinuation of therapy should be avoided, because this may cause the attacks to recur.

During long-term therapy in elderly patients, regular monitoring of renal function indicators is recommended; if necessary, dose adjustment is carried out depending on the results of a creatinine clearance study.

Nootropil penetrates through the filter membranes of hemodialysis machines.

Impact on the ability to drive vehicles and operate machinery

Taking into account possible undesirable effects, the patient should be careful when operating machinery and driving a car.

Active ingredient

Piracetam

Composition

One tablet contains

active substance:

piracetam 800 mg,

excipients: colloidal silicon dioxide anhydrous, magnesium stearate, polyethylene glycol 6000, croscarmellose sodium,

Shell composition: Opadry Y-1-7000-hydroxypropyl methylcellulose, titanium dioxide (E171), Opadry OY-S-29019-hydroxypropyl methylcellulose, polyethylene glycol 6000.

Contraindications

– known hypersensitivity to piracetam or pyrrolidone derivatives, as well as other components of the drug

– Huntington’s chorea

– acute cerebrovascular accident (hemorrhagic stroke)

– end-stage renal failure (creatinine clearance ˂ 15 ml/min)

– pregnancy and lactation period

– children up to 8 years of age in the complex treatment of dyslexia

Side Effects

From the side of the central nervous system: hyperkinesia (1.72%), nervousness (1.13%), drowsiness (0.96%), depression (0.83%), asthenia (0.23%). These side effects occur more often in elderly patients receiving the drug at a dose of more than 2.4 g/day. In some cases – dizziness, headache, ataxia, imbalance, exacerbation of epilepsy, insomnia, confusion, agitation, anxiety, hallucinations, increased sexuality.

From the metabolic side: increase in body weight (1.29%).

From the digestive system: in some cases – nausea, vomiting, diarrhea, abdominal pain.

Dermatological reactions: dermatitis, itching, rash, swelling.

Interaction

There was no interaction with clonazepam, phenytoin, phenobarbital, or sodium valproate. Confusion, irritability and sleep disturbance have been reported during concomitant thyroid treatment (T3+T4).

Nootropil® in high doses (9.6 g/day) increases the effectiveness of indirect anticoagulants in patients with venous thrombosis (a more pronounced decrease in the level of platelet aggregation, fibrinogen level, von Willibrand facts, blood and plasma viscosity was observed compared with the use of indirect coagulants only).

The possibility of changing the pharmacodynamics of the drug Nootropil® under the influence of other drugs is low, because 90% of the drug is excreted unchanged in the urine.

Nootropil® does not inhibit cytochrome P450 isoenzymes. Metabolic interaction with other drugs is unlikely.

When taking Nootropil® at a dose of 20 mg/day, Cmax and the nature of the pharmacokinetic curve of antiepileptic drugs (carbamazepine, phenytoin, phenobarbital, valproate) in patients with epilepsy receiving constant doses of these drugs do not change.

When piracetam was taken together at a dose of 1.6 g with alcohol, the concentrations in the blood serum of piracetam and ethanol did not change.

Overdose

Symptoms: dyspeptic symptoms such as bloody diarrhea and abdominal pain.

Treatment: immediately after taking the drug orally, you can rinse the stomach or induce artificial vomiting. Symptomatic therapy is recommended, which may include hemodialysis. There is no specific antidote. The effectiveness of hemodialysis for piracetam is 50-60%.

Storage conditions

In a dry place, at a temperature not exceeding 25 °C

Shelf life

4 years

Manufacturer

UCB Farma, Belgium